Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Complete Genomics, Inc. et al v. Illumina, Inc. et al
Case Number:
3:21-cv-00217
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 31, 2021
Illumina Antitrust Case Iced While Patents Challenged
A California federal judge has delayed a competitor's antitrust suit against Illumina until the DNA-sequencing company's patent infringement claims against the same rival are resolved.
-
February 23, 2021
Illumina Wants 'Entirely Derivative' Antitrust Suit Paused
Illumina wants a California federal judge to pause a competitor's antitrust suit so the gene-sequencing behemoth can first pursue its patent infringement suit against that same rival.
-
January 11, 2021
Illumina Hit With Antitrust Suit Over Alleged Patent Fraud
Illumina stifled competition with fraudulently obtained patents and "baseless" infringement litigation, a rival company alleged Monday in a suit filed in California federal court, accusing the gene-sequencing behemoth of maintaining U.S. market dominance by defrauding the patent office and echoing the Federal Trade Commission's proclamation that Illumina is a "monopolist."